ArticleScience (New York, N.Y.)2017
IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity.
Article in Science (New York, N.Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 250 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
250 citing papers in PubMed, 1 synthesis or guideline pooled it, 370 citations in OpenAlex.
- HLA alleles and dengue susceptibility across populations in the era of climate change: a comprehensive review.Frontiers in immunology · 2025Pooled it
- Direct Infection of B Cells by Dengue Virus Modulates B Cell Responses in a Cambodian Pediatric Cohort.Frontiers in immunology · 2020Trial
- Glycomic Signatures of Plasma IgG Improve Preoperative Prediction of the Invasiveness of Small Lung Nodules.Molecules (Basel, Switzerland) · 2019Trial
- Questioning the role of antibody-dependent enhancement in severe dengue.Nature microbiology · 2026Article
- Dengue virus infection.Nature reviews. Disease primers · 2026Review
- Afucosylated VAR2CSA-Specific IgG Reduces Risks of Placental Malaria.The Journal of infectious diseases · 2026Article
- Elevated ozone activates maternal immunity to drive offspring IgG-mediated anaphylaxis through IgG glycosylation alterations.Nature communications · 2026Article
- Functional antibody responses and protection against symptomatic dengue.Communications medicine · 2026Review
- Article
- Molecular and biophysical requirements for B cell receptor-dependent enhancement of dengue virus infection.Journal of virology · 2026Article
- Acute-Phase Dengue Antibody Profiles in Pediatric Patients: Influence on Viremia and Disease Manifestations.Viruses · 2026Article
- A novel FcγRIIa-TRIM54-STAT2 axis negatively regulates type I interferon signaling and promotes viral susceptibility in human monocytes.Journal of virology · 2026Article
- Biographical Feature: Benjamin A. Pinsky, MD, PhD.Journal of clinical microbiology · 2026Article
- Atypical B cells and inflammatory profiles delineate immunity to influenza vaccination in First Nations and non-Indigenous people with chronic multimorbidity.Nature communications · 2026Article
- The association between plasma IgG N-glycosylation and viral encephalitis in children: a hospital-based case-control study.Italian journal of pediatrics · 2026Article
- The impact of sex on the immune system explored at the single-cell level.American journal of human genetics · 2026Article
- Antibody-Dependent Immune Complex Signaling and Inflammatory Cytokine Responses in Acute Febrile Illness: A Mechanistic Study in Arboviral and Leptospiral Infection.Open forum infectious diseases · 2026Article
- Functional Antibody-Dependent Enhancement as an Immune Assessment Platform: Development, Standardization, and Translational Interpretation in Flavivirus Research.Pathogens (Basel, Switzerland) · 2026Review
- Enhancing, controlling, and sterilizing dengue immunity and the development of broadly protective responses.medRxiv : the preprint server for health sciences · 2026Article
- Development of anti-dengue virus D8 neutralizing monoclonal antibody production inBiotechnology reports (Amsterdam, Netherlands) · 2026Article
190 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
Dengue virus (DENV) infection in the presence of reactive, non-neutralizing immunoglobulin G (IgG) (RNNIg) is the greatest risk factor for dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). Progression to DHF/DSS is attributed to antibody-dependent enhancement (ADE); however, because only a fraction of infections occurring in the presence of RNNIg advance to DHF/DSS, the presence of RNNIg alone cannot account for disease severity. We discovered that DHF/DSS patients respond to infection by producing IgGs with enhanced affinity for the activating Fc receptor FcγRIIIA due to afucosylated Fc glycans and IgG1 subclass. RNNIg enriched for afucosylated IgG1 triggered platelet reduction in vivo and was a significant risk factor for thrombocytopenia. Thus, therapeutics and vaccines restricting production of afucosylated, IgG1 RNNIg during infection may prevent ADE of DENV disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.